Glialign was established in 2018 to take forward the work of UCL academics in engineering live neural tissue. Their current project has been funded by the UCL Technology Fund, UK Innovation and Science: Seed Fund (UKI2S) and Innovate UK. The founders James Phillips and John Sinden are currently optimising a method for producing a living nerve growth guide designated “EngNT”, which is intended as an ‘off-the-shelf’ nerve replacement – primarily for peripheral nerve repair. This represents an innovative engineering solution to an unmet clinical need.

Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology


Associated Team Members

Relevant News

UCL Technology Fund and UK Innovation & Science Seed Fund invest in cell therapy company Glialign

Photo Glialign CEO John Sinden London, 2nd May 2018 The UCL Technology Fund (UCLTF), UK Innovation…

read more

More Companies in Medical / Biotechnology